




# CHIEF

Cohorte prospective de patients atteints de  
Carcinome Hépatocellulaire en France

Prospective cohort of patients with hepatocellular carcinoma in France



# Locations



31 study centres

- 
- Multicentre **longitudinal** study of patients with HCC with **prospective** data collection on inclusion and patient follow-up, constitution of a **biological resources collection**.
  - **5,000 patients** will be included over 4 years
  - Maximum follow-up of patients: **5 years**

- To identify clinical, biological and pathomolecular factors determining the **efficacy of treatments** of HCC under real-life clinical practice conditions.

Endpoint :

Liver Transplant	SSR
Resection / percutaneous ablation	SSR
Chemoembolization / Radioembolization	OS
Drugs	OS

# Secondary objectives

- 
- Evaluate the **safety** and the **efficacy** of treatments of HCC under real-life clinical practice conditions.
  - Describe the aetiological, clinical, and biological **characteristics of HCC**, the modalities of diagnostic and therapeutic management, particularly concerning treatment sequences and strategies, as well as the care pathway
  - Evaluate the **impact of the treatment** sequences and strategies used on survival.
  - Evaluate the impact of the treatment sequences and strategies used on the **Quality of life**.
  - Describe the characteristics of patients immediately considered to be ineligible for specific treatment of HCC.
  - Evaluate the application of clinical practice guidelines

# Inclusion criteria

---

- New cases of HCC regardless of the cause, stage, treatment

or

- Known HCC: **only** Drug treatment or Chemoembolization or Radioembolization for recurrence or progression

---

## Data :

- follow-up during 5 years

## Tissue biopsies and Tumors


- Samples are taken according to local practices
- Standardized report

## Samples :

- Samples of blood, urine and feces
- 2 times :
  - At the inclusion
  - At the event of tumor progression

- 1<sup>st</sup> patient : 5 september 2019
- last patient : 30 september 2023
- End of follow-up (last patient) : 30 september 2028

**15 november 2022 : 3500 patients included**



100 inclusions per month on average


Final objective: 5,000 patients



# Today

# CHIEF

**Sex :**




## Patient Profiles ( 12 sept. 2022)

**Age :**


**Average :** 67 ans  $\pm 9,7$   
**Median :** 68 ans  
**Min ; Max :** 18,0 ; 93,0  
**Q1 ; Q3 :** 62,0 ; 74,0

**On 3287 patients**


**OMS at inclusion :**



**BCLC at inclusion :**



**CHILD at inclusion :**




## Communications

### Project : **ELITor**

**Title :** DISEASE BURDEN OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: OUTCOMES RESEARCH FROM THE FRENCH CHIEF COHORT

- ILCA sept. 2021 : oral communication
- AFEF sept 2021 : Poster + oral communication oral
- AASLD nov. 2021 : Poster
- 1<sup>er</sup> Draft publication on going



### Project : **Cabometix (Pr Sébastien Dharancy)**

**Title :** Observatory of use and sequencing of Cabozantinib in clinical practice in the North-West inter-region (Lille-Amiens-Caen-Rouen) within the CHIEF cohort.

- AFEF sept 2021 : Poster

## 3 projects on going

**Project : SANOFI PBMC**

**Title :** Etude Pilote

**Coordination:** SANOFI

**=> First result in progress**

**Project : Social CHIEF**

**Title :** Influence of social determinants of health on the management of hepatocellular carcinoma in the French national CHIEF cohort.

**Coordination :** Charlotte COSTENTIN

**Objective :** The main objective will be to evaluate the rate of curative treatment in first-line treatment (resection, ablation or liver transplantation) according to the social determinants of health in patients with HCC

**=> In progress: more than 400 patients included**

**Project : Epidemio 2000 CHIEF**

**Title :** description and epidemiology of HCC patients included in the CHIEF cohort

**Coordination :** Eric NGUYEN-KHAC

**Objective :** Describe the HCC patient population within the CHIEF cohort

**=> Publication coming soon**

---

## 8 projects in preparation

- Sequences of systemic treatments in carcinoma (1 project)
- Hepatocellular carcinoma and viral B infection (1 project)
- Atezolizumab and Bevacizumab in hepatocellular carcinoma (5 projects)
- Hepatocellular carcinoma and artificial intelligence (1 project)

---

5 000 patients with HCC in follow-up (all origine, all treatment)

## Opportunities :

- Prospective data
- Data in full mutation of medical practices in the HCC
- National representativeness

**Work with us !**

[chief@chu-amiens.fr](mailto:chief@chu-amiens.fr)